Showing titles in Physical Illness & Disease

Eli Lilly's Zepbound delivers up to 21% weight loss through a groundbreaking dual-hormone mechanism that's reshaping obesity treatment. Join host Julia Cartwright as she decodes the science, clinical trial results, and real-world access barriers behind this revolutionary injection. Each episode stands alone, exploring a different facet of medicine's newest metabolic game-changer. For more content like this, visit QuietPlease.ai

Explore the groundbreaking science behind GLP-1 drugs and addiction with Dr. Ben Synth. From shared brain reward pathways to landmark veteran studies, discover how medications for diabetes and weight loss may revolutionize treatment for alcohol, opioid, nicotine, and gambling addiction. Evidence-based insights into psychiatry's most promising frontier. For more content like this, visit QuietPlease.ai

Host Julia Cartwright examines what clinical trials and real-world data actually reveal about Ozempic and GLP-1 weight loss results, cutting through social media hype. From realistic timelines and body composition changes to the gap between viral posts and science, she delivers an evidence-first look at what users can genuinely expect. For more content like this, visit QuietPlease.ai

Dr. Ben Synth uncovers how Ozempic and similar GLP-1 medications are unexpectedly changing users' relationship with alcohol—from vanishing cravings to potential addiction treatment applications. This three-part series explores the neuroscience, safety risks, and surprising medical possibilities when diabetes drugs meet drinking habits. For more content like this, visit QuietPlease.ai

Dr. Ben Synth investigates why Ozempic keeps disappearing from pharmacies despite explosive demand. This series explores the supply chain crisis triggered by 442% prescription growth, the dangerous counterfeit market filling the gaps, and Novo Nordisk's massive $16 billion manufacturing expansion racing to catch up. For more content like this, visit QuietPlease.ai

Dr. Ben Synth investigates whether GLP-1 drugs like Ozempic cause cancer or prevent it, untangling rodent studies, FDA warnings, and surprising evidence that these medications might actually protect against obesity-related tumors. Discover why the truth is far more nuanced than headlines suggest. For more content like this, visit QuietPlease.ai

Eli Lilly's orforglipron achieved 27 pounds of weight loss in trials, potentially revolutionizing obesity treatment with a daily pill that needs no refrigeration. Dr. Ben Synth examines the science behind oral GLP-1 drugs, their potential to democratize access worldwide, and the dangers of unregulated compounded alternatives that harmed hundreds of patients. For more content like this, visit QuietPlease.ai

When bariatric surgery doesn't maintain weight loss long-term, can Ozempic fill the gap—or does stacking two powerful interventions create dangerous new risks? Dr. Ben Synth unpacks the clinical evidence, patient outcomes, and medical debate surrounding this controversial weight-loss combination. For more content like this, visit QuietPlease.ai

Discover why rapid weight loss from GLP-1 medications like Ozempic can lead to dramatic facial aging. Julia Cartwright explores the science of facial fat loss, the cosmetic treatments racing to reverse it, and who's most at risk for this unexpected side effect. For more content like this, visit QuietPlease.ai

Host Pennie Power cuts through the confusion surrounding Medicare's 2026 GLP-1 Bridge Program, revealing which weight loss medications actually qualify, who's eligible based on BMI and health conditions, and the real costs beyond the $50 copay. Get the facts you need before coverage launches. For more content like this, visit QuietPlease.ai

Miss Olivia Harper investigates whether GLP-1 drugs like Ozempic and Wegovy belong in pediatric medicine, exploring clinical trial data, doctor perspectives, and the real-world stakes for teens navigating obesity, identity, and a treatment with unknown long-term effects. For more content like this, visit QuietPlease.ai

Wealth and Hellness takes an intimate look into the state of our current healthcare system and the multi trillion dollar health and wellness industry that accompanies it and often files patients into it. We breakdown structural issues within the system and what values lie below those issues while brushing on topical questions like should I be taking vitamins??? At the end of the day you will come away from this podcast more discerning of misinformation put out by this booming industry and more empowered to pursue true health and wellness for yourself.

Host Julia Cartwright dissects official medical reports and boasts about cognitive tests, consulting independent doctors to separate political spin from clinical reality. What do Trump's health disclosures reveal—and what critical information remains hidden as the oldest president in history governs into his eighties? For more content like this, visit QuietPlease.ai

Maxwell Slate investigates bombshell claims that Trump made false statements disconnected from reality during cabinet meetings, separating lies from possible memory failure. Through clinical analysis of confabulation, fact-checker documentation, and ethical debates over remote diagnosis, the series asks whether fiction in the Cabinet Room signals deliberate deception or something far more troubling. For more content like this, visit QuietPlease.ai

Benvenuti su Retina On-Air, lo spazio editoriale audio ufficiale della GIVRE (Gruppo Italiano di Chirurgia Vitreoretinica). In un mondo medico che corre alla velocità della luce, questo podcast nasce per fermare il tempo e dare voce all'eccellenza dell'oftalmologia italiana.Il FormatCondotto dal Prof. Rodolfo Mastropasqua e dal Dr. Ruggero Tartaro, il podcast ospita i più illustri chirurghi vitreoretinici per un dialogo che va oltre la semplice letteratura scientifica. Ogni episodio è un’immersione profonda nella carriera e nella mente dei grandi maestri, analizzando il binomio ...

Host Alexandra Reeves cuts through viral hoaxes and social media noise to investigate what's really known about President Trump's health in 2026. From debunked hospital rumors to documented physical symptoms, this series separates medical facts from internet speculation and examines why presidential health transparency matters more than ever. For more content like this, visit QuietPlease.ai

Dr. Ben Synth reveals why up to 15% of patients see little benefit from Ozempic and similar GLP-1 medications, exploring genetic factors, gut microbiome differences, and real-world adherence challenges. Discover the cutting-edge science explaining who responds to these blockbuster weight-loss drugs and who doesn't. For more content like this, visit QuietPlease.ai

This podcast is hosted by two passionate pediatric urologists, Dr. Albert and Dr. Mike, who explore and discuss various pediatric urological conditions through honest conversations. Contents are educational in nature and should not be considered medical advice

Discover the life and career of Mike Sicilia, one of the most influential executives in enterprise technology, healthcare innovation, and artificial intelligence, on Mike Sicilia - Biography Flash. Hosted by AI host Vanessa Clark, this podcast delivers an in-depth biography of the Oracle executive who oversees industry-specific cloud solutions and AI-powered applications across healthcare, life sciences, retail, financial services, hospitality, energy, local government, and more. From his computer science education at Saint Joseph's University in Philadelphia to his roots at Primavera Systems ...

Discover why the identical molecule semaglutide exists as two blockbuster drugs with different names, doses, and purposes. Julia Cartwright demystifies Ozempic and Wegovy, revealing the FDA approvals, dosing strategies, insurance battles, and clinical evidence that separate diabetes treatment from weight management. For more content like this, visit QuietPlease.ai